Popular topics to explore
“Why No-Trade Can Be a Smart Decision” .
Trading is not about finding an opportunity in every market condition. Sometimes price action remains unclear, volatility becomes unpredictable or the risk-to-reward relationship does not justify taking a position. In such situations, stayi…
12th Sep · SEBI Registration INH000018142
SEBI Registration INH000018142 · 12th Sep
Bharat Health Expo 2026: Pharma & Supply Chain
Speaking at the Bharat Health Global Expo 2026 in New Delhi, Union Minister of Commerce and Industry Piyush Goyal called for India to transform its pharmaceutical leadership by moving beyond generic drugs toward research, innovation, and re…
Divi’s Laboratories (DIVISLAB) has delivered a very strong
DIVISLAB Divi’s Laboratories (DIVISLAB) has delivered a very strong Q1 FY27. Revenue from operations increased 27.8% YoY to ₹3,080 crore, while consolidated PAT jumped 65.5% to ₹902 crore. Operating profitability improved sharply, with o…
“Why Overconfidence Can Be as Dangerous as Fear”
Fear is often discussed as a major problem in trading, but overconfidence can create equally damaging decisions. After a series of successful trades, a trader may begin to believe that the next trade is also likely to succeed. This can lead…
Divi’s Laboratories Extends Its Breakout, positive Trend
DIVISLAB is showing one of the cleaner continuation structures within the pharmaceutical and contract-manufacturing space. The broader pharma theme remains supported by global outsourcing, supply-chain diversification, rising demand for c…
Morepen Labs Completes Phase-1 Capacity Expansion
MOREPENLAB has successfully completed the first phase of its manufacturing capacity expansion programme ahead of schedule. The company’s installed reactor capacity for API and CDMO operations has increased from 535 KL to 614 KL.
The ea…
Innova Captab Board OKs ₹50 Cr Land Acquisition
INNOVACAP Board of Directors has accorded in-principle approval for the acquisition of land with an estimated investment of approximately ₹50 crore.
The proposed land purchase forms part of the company’s strategic real estate expansion…
A strong stock can outperform a weak market.
industry growth, earnings momentum, and investor confidence align together. Imagine the market is walking through a storm. The Nifty is under pressure, crude oil is rising, and sentiment is cautious. Yet, some companies continue climbing.…
Divi's Laboratories - Bearish Divergence, Profit booking can be seen
I see the uptrend in DIVISLAB looking increasingly stretched after the sharp rally from the ₹5,800–6,000 zone. While price has pushed towards ₹8,600, MACD has started giving a bearish crossover and the momentum is showing divergence — pri…
“Why Market Acceptance Can Confirm a Breakout”
A breakout becomes more meaningful when price holds the new territory instead of immediately reversing. Look for: Strong closes beyond the level Price holding above or below the breakout zone Continued participation Follow-through after a…
14th Aug · SEBI Registration INH000016913
SEBI Registration INH000016913 · 14th Aug
India’s Drug Law Is Changing: Who Could Benefit?
Imagine a drug factory operating for more than a decade, while the central regulator doesn’t even have it properly recorded in its database. That is the bigger problem with India’s old drug-regulation system: fragmentation, weak informatio…
14th Aug · SEBI Registration INH000016913
SEBI Registration INH000016913 · 14th Aug
India’s 86-Year-Old Drug Law Is Finally Being Rewritten
Imagine buying a medicine for a child and assuming one thing: the system has already checked it. Recent cough-syrup tragedies showed why that assumption cannot always be taken for granted. India’s 1940 Drugs and Cosmetics Act is now 86 yea…
DIVI'S LAB Results Analysis-Q1FY27
DIVISLAB Financial performance and key Operating Metrics (Consolidated) :
Operating Revenue for Q1FY27 is Rs. 3,080 Crs., 27.8% growth YoY, Total Income is Rs. 3,144 Crs., 24.32% growth YoY, Gross Profit is Rs. 2,094 Crs., 44.02% growth Y…
JULY MARKET SCORECARD---> July's Sector Winners & Losers: Who Won the Rally?
July 2026 was a month of clear sector rotation in the Indian market. The numbers tell an interesting story. --------> Sector Performance — July 2026 Sector / Index July Performance IT +14.7% Consumer Durables +9.3% Real Estate +8.6% Auto +…
!divis Capacity expansion and future growth
DIVISLAB 1. Strong demand in custom synthesis business
Divi's continues to witness healthy demand from global pharmaceutical innovators for custom synthesis and contract manufacturing services.
This segment remains one of the company's hi…
“Why Price Behavior Around Key Levels Matters Most”
Support and resistance are not just lines on a chart. They are areas where buyers and sellers compete for control. What to observe: How quickly price reacts Whether candles close beyond the level If volume increases during the test Whethe…
3rd Aug · SEBI Registration INH000015835
SEBI Registration INH000015835 · 3rd Aug
!TC, Bajaj Finance and Divi's Labs lead gains
TC, Bajaj Finance and Divi's Labs lead gains ITC climbed despite a decline in quarterly profit, as investors welcomed strong cigarette volume growth. Bajaj Finance, Bajaj Finserv, and Divi's Laboratories were among the top gainers followin…
3rd Aug · SEBI Registration INH000022136
SEBI Registration INH000022136 · 3rd Aug
Shares of Divi's Laboratories Ltd. (NSE: DIVISLAB) advanced up to 4% on August 3, 2026
DIVISLAB
Q1 Financial & Operational Highlights
The company delivered exceptional top-line and bottom-line growth, heavily fueled by its Custom Synthesis division.
Consolidated Growth: Revenue surged 28% year-over-year (YoY). Net profit j…
FII UPDATE-----> Foreign Investors Are Back! After 4 Months of Selling, FPIs Return With ₹20,200 Crore. Is This the Start of a New Rally?
After four consecutive months of net selling, Foreign Portfolio Investors (FPIs) turned net buyers in July, investing nearly ₹20,200 crore into Indian equities. The reversal comes as improving macroeconomic conditions, easing global concern…
Q1 Earnings Snapshot:-----> DIVISLAB & MUTHOOTFIN Deliver Strong Numbers. Here's What you Need to Know.
Two quality companies from different sectors reported impressive Q1 results, with both posting robust growth in revenue and profitability.
Here's a quick snapshot:
Q1 Results : DIVISLAB Net Profit Rises 65.5%
Divi's Laboratories Q1 Resu…
